Advanced Filters
noise

Immune Thrombocytopenia Clinical Trials

A listing of Immune Thrombocytopenia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 88 clinical trials
H Hong Tian

Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia

The primary objective of this trial is to assess the efficacy and safety of combining Romiplostim N01 with Rituximab for the treatment of adult patients with primary immune thrombocytopenia (ITP) whose disease is refractory to oral TPO-RAs. All participants in this study will receive the same combination treatment: Rituximab: Given …

14 years of age All Phase N/A
Y Yu Hu, MD

Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP

The goal of this clinical trial is to learn if romiplostim N01 works to treat severe primary immune thrombocytopenia in adults. It will also learn about the safety of romiplostim N01. The main question it aims to answer is: TO evaluate the effectiveness of the combination treatment of glucocorticoids, gamma …

18 - 75 years of age All Phase 2
H Hua Xue, Doctor

A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP who have previously received standard corticosteroid therapy and have failed or relapsed after at least one standard ITP treatment. …

18 - 75 years of age All Phase 3
S Shuo Chen, MD

A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP

This study is a multicenter interventional research on the first-line treatment of newly diagnosed adult patients with immune thrombocytopenia (ITP) using romiplostim N01 in combination with glucocorticoids. The primary endpoint of this study is to assess the efficacy of romiplostim N01 combined with glucocorticoids in untreated newly diagnosed adult ITP …

18 - 75 years of age All Phase 2
Y Yunfei Chen, MD

Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

This prospective, multicenter, randomized study aim to evaluate the efficacy and safety of romiplostim N01 combined with glucocorticoids as the first-line treatment for newly diagnosed adult primary immune thrombocytopenia (ITP).

18 - 75 years of age All Phase 2

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally …

18 years of age All Phase 1/2
Y Yongzhi Zheng, PhD

Short-course High-dose Prednisone and Dexamethasone in Children With ITP

Comparison of the efficacy and safety of short-course high-dose prednisone and dexamethasone in the treatment of children with newly diagnosed immune thrombocytopenia (ITP)

29 - 14 years of age All Phase 4

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) …

18 - 85 years of age All Phase 1
S Shaohua Le, Master

Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate

29 - 14 years of age All Phase 4
M Matthieu MAHEVAS, PHD

IgIV Plus Prednisone vs High-dose Dexamethasone for ITP

ITP patients with low platelet count and active bleeding symptoms are at risk of life-threatening bleeding and therefore require a treatment with a rapid effect, reliable, and sustained. The combination of intravenous immunoglobulin (IVIg) and prednisone (1 mg/kg per day), is more rapidly and more frequently effective than high dose …

18 - 80 years of age All Phase 3

Simplify language using AI